AstraZeneca shares rise

AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
AstraZeneca shares rise as China probe update reassures
Investors were reassured after the drugmaker said a potential fine in China would have only a minor business impact.The company said it could face a charge of up to $4.5 million in the country over suspected unpaid import taxes for two cancer drugs.
AstraZeneca sales jump despite troubles in China
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It also cited annual budget caps at Chinese hospitals.
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more
AstraZeneca CEO says company has no access to executive Wang, in detention in China
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
STAT8h
Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super ...
Pharmaceutical giant AstraZeneca faces potential fines in China over import taxes
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site
The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million ...
Revenues, profits surge at AstraZeneca
AstraZeneca posted forecast-beating numbers on Thursday, fuelled by strong demand for its cancer and cardiometabolic drugs.
AstraZeneca continues to ‘fully cooperate’ with Chinese authorities
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...
AstraZeneca faces potential fines in China over import taxes
Drugmaker AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales ...
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (NASDAQ:AZN) shares gained in European trading on Thursday after the Anglo-Swedish drugmaker reported better-than-expected Q4 2024 results and addressed investor concerns over an ...